A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT)
Year: 2006
Type: article
Abstract: Velafermin (CG53135-05 or recombinant human fibroblast growth factor-20) is under investigation for the prevention of oral mucositis (OM). OM is a common side effect in patients (pts) receiving high-dose chemotherapy (HDCT) with or without total body irradiation (TBI) as conditioning regimen for AHSCT. Preclinical studies have demonstrated that velafermin promotes epithelial and mesenchymal cell proliferation in vitro and that a single dose of velafermin had activities in reducing the severity and duration of OM as effective as multiple doses.
Institutions: University of Arkansas at Fayetteville, Cornell University, Weill Cornell Medicine, Wake Forest University, Fred Hutch Cancer Center, Virginia Commonwealth University, Oregon Health & Science University, Cleveland Clinic, Northwestern University, Temple University, University of Kansas Medical Center, University of Rochester Medicine, University of Rochester, Duke Medical Center, University of Pennsylvania, University of Miami, University of Miami Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W1974909514